title: [Ulcerative colitis: exceptional consequence after rituximab therapy].
abstract: BACKGROUND
  Possible adverse complications related to rituximab (RTX) are low, some of which are extremely rare. The authors describe one situation visibly waning exceptional treatment with RTX for SLE refractory to conventional therapies.
  
  
  CONCLUSIONS
  The authors report a patient of 34 years followed for months for an illness in its bullous lupus, with cutaneous, articular, hematologic and immunologic. Given a corticosteroid resistance, several therapeutic background based hydroxychloroquine, cyclophosphamide and methotrexate, were initiated without any improvement. Immunomodulatory therapy type RTX was introduced to this form refractory at a rate of 375mg/m(2)/week. The waning of the second infusion, the patient presented a sudden intense abdominal pain syndrome, revealing an acute catarrhal appendicitis. At distance from the appendectomy, the consequences of which were favorable, treatment with RTX was resumed. In the aftermath of the third infusion, the patient presented in table tract marked by profuse watery diarrhea whose explorations reveal a morphological endoscopic appearance of erythematous, ulcerative colitis, reversible upon discontinuation of treatment. Histological data revealed important infiltrates composed mainly of CD8T lymphocytes.
  
  
  CONCLUSIONS
  Gastrointestinal immunological consequences to the requirements of the targeted therapies deserved very careful and rigorous monitoring. However, at the slightest sign of digestive, a detailed morphological exploration is essential, to avoid in particular surgical emergency, evolution without treatment could engage in short-term vital prognosis.
authors.affiliation: Département de Médecine Interne B, Hôpital Militaire D'instruction Med V, Rabat, Maroc. sekkach@hotmail.com
authors.forename: Y
authors.initials: Y
authors.lastname: Sekkach
authors.forename: S
authors.initials: S
authors.lastname: Hammi
authors.forename: M
authors.initials: M
authors.lastname: Elqatni
authors.forename: J
authors.initials: J
authors.lastname: Fatihi
authors.forename: M
authors.initials: M
authors.lastname: Badaoui
authors.forename: N
authors.initials: N
authors.lastname: Elomri
authors.forename: F
authors.initials: F
authors.lastname: Mekouar
authors.forename: J
authors.initials: J
authors.lastname: Smaali
authors.forename: M
authors.initials: M
authors.lastname: Jira
authors.forename: T
authors.initials: T
authors.lastname: Amezyane
authors.forename: A
authors.initials: A
authors.lastname: Abouzahir
authors.forename: D
authors.initials: D
authors.lastname: Ghafir
mesh_terms: D015746:Abdominal Pain / Q000209:etiology; D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects* / Q000627:therapeutic use; D018414:CD8-Positive T-Lymphocytes; D003093:Colitis, Ulcerative / Q000139:chemically induced* / Q000473:pathology; D003106:Colon / Q000473:pathology; D003967:Diarrhea / Q000139:chemically induced; D006801:Humans; D007150:Immunohistochemistry; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy; D008297:Male; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab